Home Featured Page 212

Featured

Latest

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples Therapy

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

1...211212213...308 Page 212 of 308

EDITOR PICKS

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples Therapy

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

EDITOR PICKS

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY